Galderma has received FDA approval for Restylane Contour for the correction of temple hollowing, a focused indication that opens a new anatomical zone for the company's volumizing HA platform. Restylane Contour is a cohesive, cross-linked hyaluronic acid formulation engineered for structural support in areas requiring lift and projection—distinct from softer, more diffuse fillers used for fine lines.
Injectables
Galderma's Restylane Contour Cleared for Temple Hollowing — New Indication, Familiar Filler
Galderma expands Restylane's approved uses; temple augmentation becomes a mainstream injectable procedure.
Temple hollowing now has an FDA-cleared filler indication; practices must update protocols and training.
Temple volume loss is a recognized marker of age and a frequent patient complaint, yet it has remained underserved by cleared indications. Off-label use of volumizers has been standard practice, but a cleared indication removes prescriber liability and simplifies reimbursement conversations (where applicable). For practices, this means adding temple augmentation to your standard consultation checklist and training staff on patient selection and injection technique in a delicate zone near the temporal artery and superficial temporal nerve. Restylane Contour's approval here directly competes with Juvéderm's existing temple-use data and Revance's RHA Dynamic fillers, which also carry temple/midface indications. The real differentiation lies in your injection technique and patient outcomes—not the label alone.
Source: original report ↗
Frequently asked questions
Is Restylane Contour FDA approved for temples?
Yes, Galderma received FDA approval for Restylane Contour specifically for the correction of temple hollowing. This is a new cleared indication that removes off-label liability and simplifies reimbursement conversations for practices offering this procedure.
What's the difference between Restylane Contour and other fillers for temple augmentation?
Restylane Contour is a cohesive, cross-linked hyaluronic acid formulation engineered for structural support and lift in areas requiring projection. It competes with Juvéderm and Revance's RHA Dynamic fillers, which also have temple indications, but differentiation comes down to injection technique and patient outcomes rather than the label alone.
Why is temple volume loss a common patient complaint?
Temple volume loss is a recognized marker of aging and a frequent aesthetic concern, yet it has historically remained underserved by cleared indications. Off-label use of volumizers has been standard practice, making this new approval a significant addition to mainstream injectable procedures.
What do I need to know about injecting fillers in the temple area?
Temple injection requires careful technique due to proximity to the temporal artery and superficial temporal nerve. Staff training on patient selection and proper injection technique in this delicate zone is essential before offering temple augmentation as a standard procedure.
Does temple filler approval change how I market this procedure?
Yes—the cleared indication means you can now add temple augmentation to your standard consultation checklist without off-label concerns. This simplifies patient conversations, removes prescriber liability, and makes reimbursement discussions more straightforward where applicable.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Seasoned Expat Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.